


## A Dual Modality $^{99m}\text{Tc}/\text{Re(I)}$ -Labelled T140 Analogue for Imaging of CXCR4 Expression

William L. Turnbull, Lihai Yu, Emily Murrell, Mark Milne, Carlie Charron, Leonard G. Luyt

### Table of Contents

<b>Figure S1</b> – $^1\text{H}$ NMR spectrum (400 MHz; $\text{CDCl}_3$ ) of compound <b>5</b> (DPA-Naph-OH). .....	S2
<b>Figure S2</b> – $^{13}\text{C}$ NMR spectrum (100 MHz; $\text{CDCl}_3$ ) of compound <b>5</b> (DPA-Naph-OH). .....	S3
<b>Figure S3</b> – HPLC chromatogram (10-70% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ + 0.1% TFA) of peptide <b>6</b> (T140). ...	S4
<b>Figure S4</b> – HPLC chromatogram (20-80% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ + 0.1% TFA) of peptide <b>7</b> (DPA-Naph-T140). .....	S4
<b>Figure S5</b> – HPLC chromatogram (20-80% $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ + 0.1% TFA) of peptide <b>Re-7</b> ( $\text{Re}(\text{CO})_3$ -DPA-Naph-T140). .....	S5
<b>Table S1</b> – <i>Ex vivo</i> biodistribution data for [ $^{99m}\text{Tc}$ ] <b>Tc-7</b> in NOD/SCID mice two hours post-injection. ....	S5
<b>Figure S6</b> – Serum stability of <b>7</b> (left) and <b>Re-7</b> (right). .....	S6



**Figure S1** – <sup>1</sup>H NMR spectrum (400 MHz; CDCl<sub>3</sub>) of compound **5** (DPA-Naph-OH).







Figure S2 – <sup>13</sup>C NMR spectrum (100 MHz; CDCl<sub>3</sub>) of compound 5 (DPA-Naph-OH).



**Figure S3** – HPLC chromatogram (10-70%  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  + 0.1% TFA) of peptide **6** (T140).




**Figure S4** – HPLC chromatogram (20-80%  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  + 0.1% TFA) of peptide **7** (DPA-Naph-T140).



**Figure S5** – HPLC chromatogram (20-80% CH<sub>3</sub>CN/H<sub>2</sub>O + 0.1% TFA) of peptide **Re-7** (Re(CO)<sub>3</sub>-DPA-Naph-T140).

**Table S1** – *Ex vivo* biodistribution data for [<sup>99m</sup>Tc]Tc-7 in NOD/SCID mice two hours post-injection

Tissue	Uptake (% ID/g ± SD)
blood	1.91 ± 0.16
heart	0.93 ± 0.04
lung	2.80 ± 0.63
liver	22.67 ± 5.02
spleen	2.05 ± 1.37
pancreas	1.15 ± 0.54
stomach	4.67 ± 0.99
intestine	2.36 ± 1.40
kidney	25.69 ± 15.19
tumor	0.51 ± 0.09
muscle	0.26 ± 0.07
brain	0.10 ± 0.02



**Figure S6** – Serum stability of 7 (left) and Re-7 (right).

### Serum Stability Procedure

Peptides were dissolved to a 1 mM final concentration in 25% human serum in PBS (pH 7.4, 450  $\mu$ L final volume, DMSO final concentration 0.5%) and incubated at 37  $^{\circ}$ C. At 0, 1, 2, 4, 6, and 24 hours, 15  $\mu$ L aliquots of peptide solution was removed and mixed with 40  $\mu$ L of 4% ammonium hydroxide (pH 11-13) to dissociate peptide interactions with components of human serum. Peptides were isolated from human serum by column separation on Oasis<sup>®</sup> HLB sorbent 96-well  $\mu$ Elution plate and eluted using 20% methanol in water. The extracted peptide was quantified on an Acquity UHPLC-MS system (Waters Co.). Intact peptide was quantified by measuring the peak area of a peptide specific  $[M]^{3+}$  ion peak (average of 3 replicates). Percent abundance of peptide peak area relative to peptide peak abundance at  $T_0$  was calculated and plotted as a function of time.